This story was co-published with The Washington Post. Medicare’s prescription drug program spent nearly $4.6 billion in the first half of this year on expensive new cures for the liver disease hepatitis C — almost as much as it spent for all of 2014. Rebates from pharmaceutical companies — the amounts of which are confidential —…
This post was imported from a legacy archive. Please excuse any formatting inconsistencies.
Share this:
- Click to share on Facebook (Opens in new window) Facebook
- Click to share on X (Opens in new window) X
- Click to print (Opens in new window) Print
- Click to email a link to a friend (Opens in new window) Email
- Click to share on LinkedIn (Opens in new window) LinkedIn
- Click to share on WhatsApp (Opens in new window) WhatsApp
- Click to share on Nextdoor (Opens in new window) Nextdoor
- Click to share on Pinterest (Opens in new window) Pinterest
- Click to share on X (Opens in new window) X
- Click to share on Telegram (Opens in new window) Telegram